[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Dupilumab, a fully human monoclonal antibody that blocks the interleukin-4 and interleukin-13 pathways, is approved for the treatment of five diseases marked by type 2 inflammation that are often ...

Dupilumab, a fully human monoclonal antibody, blocks the alpha subunit of the interleukin-4 receptor and inhibits signaling by interleukin-4 and interleukin-13. 16,17 It is approved for the ...

Since its release in 2017, dupilumab (a fully humanized monoclonal antibody that blocks IL-4 and IL-13) has transformed the therapeutic landscape for managing atopic dermatitis (AD) and other ...

No antibodies to dupilumab were detected in any other patients. Adverse event incidence ranged from 73% to 100% across the study groups and parts. Most were mild or moderate.

The FDA has approved these four biologics to treat atopic dermatitis: dupilumab, lebrikizumab, nemolizumab, and tralokinumab. They are all types of biologics called monoclonal antibodies.

Dupilumab, a fully human monoclonal antibody, works by inhibiting the signaling of the interleukin 4 (IL-4) and IL-13 pathways and is approved for many conditions characterized by type 2 ...

Dupilumab is a monoclonal antibody that acts to inhibit part of the inflammatory pathway, blocking interleukin-4 and -13 receptors. "As researchers and clinicians have gained knowledge about ...

Children aged 1 to 11 years with eosinophilic esophagitis safely achieved histologic disease remission after 16 weeks of treatment with the fully human monoclonal antibody dupilumab, according to ...

A randomized placebo-controlled study found the monoclonal antibody dupilumab (Dupixent) led to histologic remission in significantly more affected children than placebo.

This monoclonal antibody is the first biologic shown to improve clinical outcomes in COPD. The data supporting the use of dupilumab in COPD will be reviewed by the United States Food and Drug ...